Dr. Rajasingham an Infectious Diseases physician and Assistant Professor of Medicine at the University of Minnesota. Her primary research interest is to maximize the public health impact of screening HIV-infected persons for opportunistic infections in order to decrease HIV/AIDS-related mortality. She particularly interested in the evaluation of cost-effective diagnostics and treatment algorithms to care of persons with advanced HIV disease.

Dr. Rajasingham received formal training from the Harvard School of Public Health in Global Health Delivery, and has spent one year in Uganda working as a clinical research coordinator for an NIH-sponsored clinical trial investigating the optimal timing of antiretroviral therapy in HIV-infected persons with cryptococcal meningitis (COAT Trial). Over the past twelve years, she has worked closely with the Ugandan and American collaborative research team at the Infectious Disease Institute (IDI) in Kampala, Uganda.  Dr. Rajasingham has led an international consortium to estimate the global burden of cryptococcal infection. She has evaluated the cost-effectiveness of a Ugandan national CRAG screening program, and performed a budgetary impact analysis for funders to estimate costs and diagnostics tests required for persons with advanced HIV disease in sub Saharan Africa. She has consulted for the Pan American Health Organization (PAHO) and UNITAID for health economics evaluations of novel point-of-care diagnostics among persons with advanced HIV disease. She is the co-PI of a phase III randomized clinical trial in Uganda evaluating the efficacy of high dose AmBisome to prevent cryptococcal meningitis in persons with advanced HIV disease, and PI for an R01 cluster-randomized trial evaluating point-of-care diagnostics in persons with advanced HIV disease, funded by NIAID.